Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis

British Journal of Haematology

Volumn 97, Issue 1, 1997, Pages 86-93

  Reiter, Andreas ^a,d   Skladny, Heyko ^a   Hochhaus, Andreas ^a   Seifarth, Wolfgang ^a   Heimpel, Hermann ^b   Bartram, Claus R ^a   Cross, Nicholas C P ^c   Hehlmann, Rüdiger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCR rearrangement; CML; interferon ; quantitative Southern blot

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC MYELOID LEUKEMIA; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOUTHERN BLOTTING;

EID: 0030887187     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.32645.x     Document Type: Article

References (31)

1. Allan, N.C., Richards, S.M. & Shepherd, P.C.A. (1995) UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet, 345, 1392-1397.
2. Asycue, L.H., Ross, D.W., Ozer, H., Rao, K., Gulley, M.L. & Dent, G.A. (1990) Bcr/abl recombinant DNA analysis versus karyotype in the diagnosis and therapeutic monitoring of chronic myeloid leukemia. American Journal of Clinical Pathology, 94, 404-409.
3. Bartram, C.R. & Carbonell, F. (1986) Bcr rearrangement in Ph-negative CML. Cancer Genetics and Cytogenetics, 21, 183-184.
4. Bartram, C.R., Raghavachar, A., Anger, B., Stain, C. & Bettelheim, P. (1987) T lymphocytes lack rearrangement of the bcr gene in Philadelphia chromosome-positive chronic myelocytic leukemia. Blood, 69, 1682-1685.
5. Benn, P., Soper, L., Eisenberg, A., Silver, R., Coleman, M., Cacciapaglia, B., Bennett, L., Baird, M., Silverstein, M., Berger, C. & Bernhardt, B. (1987) Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 29, 1-7.
6. Blennerhasset, G.T., Furth, M.E., Anderson, A., Burns, J.P., Chaganti, R.S.K., Blick, M., Talpaz, M., Dev, V.G., Chan, L.C., Wiedemann, L.M., Greaves, M.F., Hagemeijer, A., van der Plas, D., Skuse, G., Wang, N. & Stam, K. (1988) Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia. Leukemia, 2, 648-657.
7. Cross, N.C., Melo, J.V. Lin, F. & Goldman, J.M. (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in hematological disorders. Leukemia, 8, 186-189.
8. de Klein, A., van Kessel, A.G., Grosveld, G., Bartram, C.R., Hagemeijer, A., Bootsma, D., Spurr, N.K., Heisterkamp, N., Groffen, J. & Stephenson, J.R. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 300, 765-767.
9. Fishleder, A.J., Shadrach, B. & Tuttle, C. (1989) Bcr rearrangement: potential false positive secondary to an EcoRI restriction length polymorphism. Leukemia, 10, 746-748.
10. Garicochea, B., Chase, A., Lazaridou, A. & Goldman, J.M. (1994) T lymphocytes in chronic myelogenous leukemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients. Leukemia, 8, 1197-1201.
11. Groffen, J., Stephenson, J.R., Heisterkamp, N., de Klein, A., Bartram, C.R. & Grosveld, C. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell, 36, 93-99.
12. Grossman, A., Mathew, A., O'Connell, M.P., Tiso, P., Distenfeld, A. & Benn, P. (1990) Multiple restriction enzyme digests are required to rule out polymorphism in the molecular diagnosis of chronic myeloid leukemia. Leukemia, 4, 63-64.
13. Grossman, A., Silver, R., Szatrowski, T., Gutfriend, A., Verma, R. & Benn, P. (1991) Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia, 5, 540-547.
14. Guo, J.Q., Lian, J.Y., Xian, Y.M., Lee, M.S., Deisseroth, A.B., Stass, S.A., Champlin, R.E., Talpaz, M., Wang, Y.J. & Arlinghaus, R.B. (1994) BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood, 83, 3629-3637.
15. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queißer, W., Löffler, H., Hochhaus, A., Heinze, B., Georgii, A., Bartram, C.R., Grießhammer, M., Bergmann, L., Essers, U., Falge, C., Queisser, U., Meyer, P., Schmitz, N., Eimermacher, H., Walther, F., Fett, W., Kleeberg, U.R., Käbisch, A., Nerl, C., Zimmermann, R., Meuret, G., Tichelli, A., Kann, L., Tigges, F.J., Schmid, L., Brockhaus, W., Tobler, A., Reiter, A., Perker, M., Emmerich, B., Verpoort, K., Zankovich, R., von Wussow, P., Prümmer, O., Thiele, J., Buhr, T., Carbonell, F., Ansari, H., and the German CML Study Group (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood, 84, 4064-4077.
16. Hochhaus, A., Lin, F., Reiter, A., Skladny, H., Mason, P.J., van Rhee, F., Shepherd, P.C.A., Allan, N.C., Hehlmann, R., Goldman, J.M. & Cross, N.C.P. (1996a) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood, 87, 1549-1555.
17. Hochhaus, A., Lin, F., Reiter, A., Skladny, H., van Rhee, F. Shepherd, P.C.A., Allan, N.C. Hehlmann, R., Goldman, J.M. & Cross, N.C.P. (1995) Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. British Journal of Haematology, 91, 126-131.
18. Hochhaus, A., Reiter, A., Skladny, H., Melo, J.V., Sick, C., Berger, U., Guo, J.Q., Arlinghaus, R.B., Hehlmann, R., Goldman, J.M. & Cross, N.C.P. (1996b) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. Blood, 88, 2236-2240.
19. Kantarjian, H.M., Smith, T.L., O'Brien, S., Beran, M., Pierce, S. & Talpaz, M. (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Annals of Internal Medicine, 122, 254-261.
20. Kato, Y., Sawada, H., Tashima, M., Yumoto, Y., Okuda, T., Ueda, T., Uchino, H., Hotta, T., Mitutani, S., Ono, T. & Ogawa, K. (1988) Restriction fragment length polymorphism of bcr in Japanese patients with hematological malignancies. Leukemia, 2, 701-703.
21. Kurzrock, R., Gutterman, J.U. & Talpaz, M. (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 319, 990-998.
22. BCR-ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia? Leukemia, 8, 208-211.
23. Opalka, B., Wandlm U.B., Becher, R., Kloke, O., Nagel-Hiemke, M., Moritz, T., Beer, U., Seeber, S., Niederle, N. (1991) Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon-α2b alone or in combination with interferon γ. Blood, 78, 2188-2193.
24. Ozer, H., George, S.L., Schiffer, C.A., Rao, K., Rao, P.N., Wurster-Hill, D.H., Arthur, D.D., Powell, B., Gottlieb, A., Peterson, B.A., Rai, K., Testa, J.R., Le Beau, M., Tantravahi, R. & Bloomfield, C.D. (1993) Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood, 82, 2975-2984.
25. Sambrook, J., Frisch, E.F. & Maniatis, T. (1989) Molecular Cloning: a Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory. New York.
26. Stock, W., Westbrook, C., Peterson, B., Szatrowski, T., Silver, R., Schiffer, C. & Bloomfield, C. (1993) Molecular monitoring of bcr/abl fusion gene in chronic myelogenous leukemia: peripheral blood analysis is comparable to a bone marrrow examination. Blood, 82, 331a.
27. Talpaz, M., Kantarjian, H.M., Kurzrock, R., Trujillo, J.M. & Gutterman, J.U. (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Annals of Internal Medicine, 114, 532-538.
28. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with convential chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine, 330, 820-825.
29. Tsukamoto, N., Karasawa, M., Maehara, T., Okamoto, K., Sakai, H., Naruse, T., Morita, K., Tsuchiya, J. & Omine, M. (1996) The majority of T-lymphocytes are polyclonal during the chronic phase of chronic myelogenous leukemia. Annals of Haematology, 72, 61-65.
30. Verschraegen, C.F., Talpaz, M., Hirsch-Ginsberg, C.F., Pherwani, R., Rios, M.B., Stass, S.A. & Kantarjian, H.M. (1995) Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood, 85, 2705-2710.
31. Zhao L., Kantarjian, H.M., van Oort, J., Cork, A., Trujilio, J.M. & Liang, J.C. (1993) Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment. Leukemia, 7, 168-174.